What is the 13F Pro Quality Score for MBIO?

13F Pro ranks MUSTANG BIO, INC. (MBIO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View MBIO's current score at https://13fpro.ai/research/MBIO (free sign-up required for the full ranking).

Which hedge funds own the most MBIO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of MBIO include Kestra Advisory Services,, GEODE CAPITAL MANAGEMENT,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/MBIO as soon as new 13F filings post.

Where does 13F Pro source MBIO data?

All MUSTANG BIO, INC. fundamentals and ownership data come directly from SEC EDGAR. MUSTANG BIO, INC. files with the SEC under CIK 1680048. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is MBIO in?

MUSTANG BIO, INC. (MBIO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is MBIO research updated on 13F Pro?

MBIO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

MUSTANG BIO, INC.(MBIO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1680048 MBIO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

MBIO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for MUSTANG BIO, INC. (MBIO), a Healthcare sector company. MBIO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), MUSTANG BIO, INC. reports net income of $-955.0K, free cash flow of $-1.0M. Top institutional holders of MBIO by reported 13-F value include Kestra Advisory Services,, GEODE CAPITAL MANAGEMENT,, BlackRock,, based on the most recent SEC filings. MBIO trades on the Nasdaq exchange and files with the SEC under CIK 1680048. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MUSTANG BIO, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-955.0K

Free Cash Flow

Q1 2026

$-1.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+87.8% YoY

$-1.9MFY 2025

FY22 $-77.5MFY23 $-51.6MFY24 $-15.8MFY25 $-1.9M

Operating Income

+85.0% YoY

$-2.4MFY 2025

FY22 $-76.2MFY23 $-49.3MFY24 $-16.2MFY25 $-2.4M

EPS (Diluted)

+99.0% YoY

$-0.39FY 2025

FY22 $-0.67FY23 $-299.95FY24 $-38.57FY25 $-0.39

Total Assets

+89.0% YoY

$17.6MFY 2025

FY22 $92.4MFY23 $17.7MFY24 $9.3MFY25 $17.6M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

+53.9% YoY

$-5.3MFY 2025

FY22 $-65.1MFY23 $-49.5MFY24 $-11.4MFY25 $-5.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-1.9M +87.8%	$-15.8M +69.5%	$-51.6M +33.4%	$-77.5M -16.8%	$-66.4M -10.6%	$-60.0M
Operating Income	$-2.4M +85.0%	$-16.2M +67.0%	$-49.3M +35.3%	$-76.2M -14.1%	$-66.7M -17.5%	$-56.8M
EPS (Diluted)	$-0.39 +99.0%	$-38.57 +87.1%	$-299.95 -44489.0%	$-0.67 -1226.8%	$-0.05	—
Total Assets	$17.6M +89.0%	$9.3M -47.5%	$17.7M -80.8%	$92.4M -26.2%	$125.2M +13.9%	$109.9M
Total Debt	—	—	—	—	—	$0.00
Operating Cash Flow	$-5.3M +53.9%	$-11.4M +76.9%	$-49.5M +24.0%	$-65.1M -21.2%	$-53.7M -43.8%	$-37.3M

AI Insight: MBIO Financial Trends

MBIO generates zero revenue across all eight quarters while losses stabilize near breakeven, but negative equity persisted through Q4 2024 before equity turned positive.

• Equity swung from -$9M in Q3 2024 to +$4M in Q1 2025, marking the first positive book value in the observed period.

• Operating losses narrowed dramatically from -$9M in Q2 2024 to a stable -$1M range from Q3 2024 onward.

• Revenue remains absent across all eight quarters through Q1 2026, indicating no commercial product sales whatsoever.

⚠ Equity dipped slightly from $10M in Q3–Q4 2025 to $9M in Q1 2026 — early signs of renewed erosion worth monitoring.

⚠ Operating cash outflows persist at -$1M to -$2M every quarter with no revenue offset — runway depletion risk remains.

AI Insight: MBIO Ratio Trends

MBIO's return metrics deteriorated sharply in Q1 2026, with ROIC plunging to -49.2% and ROA to -23.0% — the worst readings in the dataset.

• ROA worsened from -4.1% in Q1 2025 to -23.0% in Q1 2026, signaling accelerating asset-level losses.

• ROIC dropped from -25.5% in Q3 2025 to -49.2% in Q1 2026, the steepest single-quarter decline observed.

• ROE swung from -17.0% in Q1 2025 to -44.4% in Q1 2026, suggesting equity base erosion alongside rising losses.

⚠ Nearly all margin and profitability fields remain blank — data sparsity limits confidence in any trend assessment.

⚠ Q2 2025 ROE hit -105.4%, an outlier spike; recurrence would signal acute equity impairment.

Get alerted when MBIO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for MUSTANG BIO, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of MBIO

Kestra Advisory Services, LLC
$128.2K176,042 sh
GEODE CAPITAL MANAGEMENT, LLC
$67.5K92,790 sh
BlackRock, Inc.
$61.7K84,745 sh
CITADEL ADVISORS LLC
$38.7K53,200 sh
VANGUARD FIDUCIARY TRUST CO
$23.4K32,120 sh
VANGUARD CAPITAL MANAGEMENT LLC
$18.7K25,704 sh
CFO4Life Group, LLC
$14.9K20,461 sh
TWO SIGMA INVESTMENTS, LP
$12.2K16,754 sh
UBS Group AG
$2.7K3,659 sh
Tower Research Capital LLC (TRC)
$1.4K1,895 sh

Fund	Value	Shares
Kestra Advisory Services, LLC	$128.2K	176,042
GEODE CAPITAL MANAGEMENT, LLC	$67.5K	92,790
BlackRock, Inc.	$61.7K	84,745
CITADEL ADVISORS LLC	$38.7K	53,200
VANGUARD FIDUCIARY TRUST CO	$23.4K	32,120
VANGUARD CAPITAL MANAGEMENT LLC	$18.7K	25,704
CFO4Life Group, LLC	$14.9K	20,461
TWO SIGMA INVESTMENTS, LP	$12.2K	16,754
UBS Group AG	$2.7K	3,659
Tower Research Capital LLC (TRC)	$1.4K	1,895

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put MBIO on your watchlist

Track score changes the day MUSTANG BIO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is MBIO a good stock to buy?

13F Pro's AI-powered analysis of MUSTANG BIO, INC. (MBIO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MBIO are available on the MBIO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own MBIO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MBIO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of MUSTANG BIO, INC.'s investment landscape.